Inhibiting this axis with CSFR1 antibodies (RG7155) or receptor tyrosine kinase small molecule inhibitors (PLX5622, PLX3397, BLZ945) inhibits BC tumor growth by reducing and increasing TAM and CD8+ T cell infiltration, respectively, in extracranial BC mouse models [92]. Here, NTRK1 is linked to breast cancer.